BeOne Medicines Ltd. (ONC): R&D Expense
$2.15B
Year ended 2025-12-31
$2.29B
Trailing 12 months to 2026-06-30
+9.4%
3-year compound annual growth
+10.6%
5-year compound annual growth
+43.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.15B | +9.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $1.95B | +9.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.78B | +8.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.64B | +12.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.46B | +12.7% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $1.29B | +39.6% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $927.34M | +36.6% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $679.00M | +152.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $269.02M | +174.4% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $98.03M | +68.3% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $58.25M | +166.4% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $21.86M | n/a | 2017-03-22, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $2.15B | +9.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
| Organon & Co. (OGN) | 2025-12-31 | $366.00M | -22.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $782.74M | -11.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $95.40M | -15.0% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $550.00M | +14.3% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $186.18M | -2.4% |
Compare ONC, ELAN, OGN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗